BRIDGEWATER, N.J., June 7 The Adis journal Drugs in R&D has been transformed from fee-based access to open access (OA), according to its parent company Wolters Kluwer Pharma Solutions, Inc., a leading provider of scientific information and analytics to professionals in the pharmaceutical and biotech fields. The conversion makes Drugs in R&D the company's first publication to embrace OA. All of the journal's content published today forward will be available online free of charge.
Advertisement
"We reinvented Drugs in R&D as an open access journal to give researchers unrestricted access to all of its peer-reviewed content," said Anton van Rensburg, MSc, Editor, Drugs in R&D. "With increased pressure today for more speed and transparency in drug research and development, Drugs in R&D is an ideal outlet to further the cause by making its content publically accessible and free for all."
Advertisement
For more than 40 years, medical and scientific researchers have turned to Adis journals for their high quality, peer-reviewed content. First launched in 1999 on a subscription and pay-per-view basis, Drugs in R&D includes original research and reviews from all phases of clinical development. The journal is Medline indexed and available on both Ovid and AdisOnline providing high global visibility.
"Unlike many new-to-market OA publications Drugs in R&D is already a well regarded and trusted source of clinical information by scientific and medical researchers," said Iain Spray, Product Manager, Adis. "This makes it a high-value platform for researchers looking to make their findings available to the global research community."
The Adis team has extensive experience with rapid publication and applies this expertise to Drugs in R&D by offering an optional Rapid Publishing Service which allows publication of new research in as little as four weeks from submission. Before any submitted article is published, it must be accepted by a panel of independent peer reviewers. The company then charges a nominal fee to cover the cost of publication.
"Our conversion is but a tiny part of a much larger movement aimed at making more research available faster and to more people," added Spray.
For access, visit the journal's AdisOnline website at http://adisonline.com/drugsrd. For more information, visit the company's website at www.wolterskluwerpharma.com.
About Wolters Kluwer Pharma Solutions
Wolters Kluwer Pharma Solutions, Inc. (Bridgewater, NJ) provides clinical and healthcare data and analytics, leading medical publishing services, and market intelligence tools to professionals in the pharmaceutical, biotech, and medical device fields. The company's brands include Adis, Source® and VisionCare Group. The global publisher Adis, provides peer-reviewed journals promoting rational pharmacology and effective patient management, and offers highly respected drug and clinical trials databases. A longstanding provider of market data and healthcare analytics, Source® offers a unique set of comprehensive patient and physician-level prescribing and usage data. VisionCare Group is a publisher of business and specialty publications and producer of conferences and e-media products targeting the vision market. For more information, visit www.wolterskluwerpharma.com.
The company is a wholly owned subsidiary of Wolters Kluwer, U.S., part of Wolters Kluwer, a market-leading global information services company. Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance, and healthcare rely on Wolters Kluwer's leading, information-enabled tools and solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.
Wolters Kluwer has 2009 annual revenues of euro 3.4 billion ($4.8 billion), employs approximately 19,300 people worldwide, and maintains operations in over 40 countries across Europe, North America, Asia Pacific, and Latin America. Wolters Kluwer is headquartered in Alphen aan den Rijn, the Netherlands. Its shares are quoted on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices.
Visit our website, YouTube or follow @Wolters_Kluwer on Twitter for more information about our customers, market positions, brands, and organization.
Contact: Tom Kivett Kivett & Company Communications +1 212 727-2935 [email protected]
SOURCE Wolters Kluwer Pharma Solutions
